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Abstract
Introduction Endovascular cooling is currently used for
hypothermia treatment and fever reduction therapy. At the
same time, little is known about the risks associated to
endovascular cooling in patients treated with an endovas-
cular cooling catheter (ECC).
Methods A retrospective chart review of 122 patients with
subarachnoid hemorrhage (SAH) treated with an ECC either
for therapeutic hypothermia or for fever reduction was per-
formed. ECC-associated thromboembolic events (TEE) such
as pulmonary embolism and thrombosis were recorded and
compared between patients treated with an ECC and patients
treated only with a central venous line (CVL). Additionally,
various laboratory parameters were recorded to determine if
they might be related to the frequency of TEE’s.
Results 43 Patients were treated with an ECC and 79 with
a CVL. Patients in the ECC group suffered more frequently
from TEE (37 %) than those with a CVL (5 %). None of
the laboratory parameters was associated with an increased
TEE risk. The treatment with an ECC alone was a risk
factor for a TEE, independent from age as well as from
Hunt and Hess grade.
Conclusion Our data show that the treatment with ECC
increases the risk of TEE in SAH patients. Therefore,
especially when considered for fever reduction, non-inva-
sive devices for surface cooling should be the first choice.
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Introduction
Therapeutic hypothermia has neuroprotective effects in adults
after cardiopulmonary resuscitation [1]. Fever has been
identified as a risk factor for poor outcome in patients with
ischemic stroke [2] subarachnoid hemorrhage (SAH) [3],
intracerebral hemorrhage [4], or traumatic brain injury [5].
For targeted, long-term temperature control, endovascu-
larly based systems might have several advantages
concerning efficacy and usability compared to surface
cooling [6, 7]. The need for a central venous line, however,
calls for an adequate risk assessment and evaluation of
potential complications such as thromboembolic events
(TEE), as these might be promoted by the long-term appli-
cation of the device. Up to date, only small case series of
patients with traumatic brain injury are described concerning
this specific complication [8]. The aim of the present study
was to analyze the incidence of TEE in a large cohort of
patients with aneurysmal subarachnoid hemorrhage (SAH)
treated with endovascular cooling catheters (ECC) com-
pared to SAH patients treated with conventional central
venous lines (CVL) and to identify potential risk factors.
Methods
The study was approved by the ethics committee of the
University Hospital of Zurich. A retrospective chart review
was performed including all patients with aneurysmal SAH
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admitted to the Neurosurgical Intensive Care Unit of the
University Hospital Zurich between January 2011 and
March 2013, and treated with ECC for fever reduction or
therapeutic hypothermia. Patients with a severe concomitant
disease were excluded from the analysis. Indications for
hypothermia treatment were brain edema with intracranial
hypertension and/or symptomatic cerebral vasospasm
refractory to conventional treatment. The correspondent
treatment algorithms are previously described [9]. The fol-
lowing parameters were analyzed: patient’s clinical state at
admission by means of Hunt and Hess scale, type of catheter
(CVL or ECC), and date of catheter insertion and removal.
Deep venous thrombosis (DVT) was evaluated by sonogra-
phy if the patient showed any clinical signs of swelling, pain,
elevated skin temperature, or red/livid color of the skin at the
extremity in which the catheter was inserted or by screening
in patients with suspected high risk for TEE. Pulmonary
embolism was diagnosed with contrast-enhanced CT scan if
the patient showed any symptoms or incidentally. The fol-
lowing daily measured parameters were analyzed in the ECC
group: fibrinogen, C reactive protein (CRP), procalcitonin C
(PTC), leucocyte, and thrombocyte counts. Vena cava filter
was inserted because of DVT and coexistent strict contra-
indication for anticoagulation.
ECCs were changed routinely every 5 days or earlier if
signs of infection occurred. CVLs were changed only with
clinical signs of infection. Every patient’s individual,
continuous ECC application period, from start until end of
the treatment period (application from only one up to
several catheters), was combined to one consecutive
treatment event. If the continuous ECC treatment was
interrupted for any reason, then the patient was excluded
from the study. The day of TEE diagnosis after ECC onset
was recorded (provided the patient was still hospitalized in
our department) irrespectively of whether the TEE occur-
red during the ECC application period or afterward. If a
patient suffered from more than one TEE, then only the
first one was considered the index event. From all TEE, the
median day of occurrence was calculated. This determined
median day was applied to compare the above-cited labo-
ratory parameters in the ECC patients with TEE to those in
patients without TEE. In both groups, the laboratory
parameters collected from the median day and the 4 pre-
ceding days were averaged. Prophylaxis against TEE was
routinely performed with pneumatic stockings in combi-
nation with unfractionated heparin 5000 E/24 h cont. i.v.
started 6 h after aneurysm clipping or aneurysm coiling.
The endovascular cooling system applied was a dual
infusion lumen 8.5F 20-cm catheter (Cool Line Catheter, Zoll
Medical, California, USA). This catheter is furnished with an
additional lumen, which ends in two balloons (sized 55 mm in
length and 5 9 5 mm in diameter). The balloons are perfused
with a sterile Ringer’s lactate solution via a closed-loop tubing
system. The tubing system is connected to a temperature-
management device (Coolgard System, Zoll Medical, Cali-
fornia, USA), consisting of a temperature-adjustable water
bath (0.5–42 C) depending on the patient’s own temperature
[10]. Conventional CVL with 4- or 5-lumen (Arrow Interna-
tional Inc., Teleflex, Durham, NC, USA) were applied in all
patients.
Statistical analysis
Patient characteristics, as well as fibrinogen, leucocyte,
thrombocyte count, CRP, PCT values, and severity (Hunt and
Hess grade) were compared using Mann–Whitney-U test.
Binomial variables were compared between the groups by
the Chi-square test or Fisher’s exact test where appropriate.
A value of p < 0.05 was regarded as statistically significant.
Bivariate logistic regressions were used to test the predictive
power of treatment with ECC for the development of TEE
independently of age and Hunt and Hess grade. Calibration
of the models was assessed using the Hosmer–Lemeshow
test. Odds ratios (OR) were reported with 95 % confidence
intervals (CI). Full multiple logistic regressions were not
performed because of the small number of events. IBM SPSS
Statistics 21.0, Armonk, NY was used.
Results
A total of 122 patients with (SAH) were analyzed. 117 patients
suffered from aneurysmal, and 5 from non-aneurysmal SAH.
Mean age of the patient population was 57.1 ± 12.2 years,
severity grade according to Hunt and Hess was in mean
2.9 ± 1.3. Endovascular cooling catheters (ECC) were
applied in 43 patients, either for fever treatment (22 patients)
or therapeutic hypothermia (21 patients). During the same
time period, 79 patients were not treated with ECCs and used
as control group. In these patients, only CVL were routinely
applied. All ECCs were inserted into the femoral vein,
whereas CVLs were inserted either in the subclavian (69
cases) or in jugular vein (10 cases). Patients in the ECC group
(53.1 ± 9.7 years) were younger than those in the CVL group
(59.3 ± 12.9, p = 0.004). With 3.6 ± 1.2, the Hunt and Hess
grade in the ECC group was higher than in the CVL group with
2.5 ± 1.2 (p < 0.001). Overall, 20 patients (16 %) died.
Among them, 12 patients died under withdrawal of treatment
due to brain herniation and/or multiple infarctions, 7 patients
died with the signs of multiorgan failure due to sepsis syn-
drome, and 1 because of a rebleeding. Mortality in patients
with ECC was higher (14 among 43; 33 %) compared to those
with CVL (6 among 79; 8 %; p < 0.001). There was no
significant difference in mortality between patients treated for
fever (6 among 21; 29 %) compared to those treated with
hypothermia (9 among 22; 41 %).
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Patients in the ECC group suffered more frequently
from TEE (37 %) than those with CVL (5 %) (p < 0.001)
(Table 1). Thrombosis, confirmed by sonography, occurred
more frequently in the ECC group (26 %) compared to the
CVL group (5 %) (p < 0.001). Thrombosis occurred sig-
nificantly more frequently in patients treated for fever
(52 %) than in patients treated with hypothermia (23 %)
(p = 0.044). Pulmonary embolism, confirmed with con-
trast-enhanced CT scan, occurred in 5 patients of the ECC
group and in 2 patients of the CVL group (p = 0.039).
Pulmonary embolism tended to occur more frequently
in patients treated for fever, although without statistical
significance. Because of strict contraindication for antico-
agulation, 6 patients, all in the ECC group treated for fever,
were protected against pulmonary embolism with cava
filters inserted into the inferior caval vein. All of them were
on prophylaxis with heparin.
The treatment with ECC alone was a risk factor for TEE
independent from age (OR 12.5, 95 % CI 3.6–43.5);
p < 0.001) as well as from Hunt and Hess grade (OR 8.9,
95 % CI 2.5–31.25; p = 0.001).
The median day for the occurrence of TEE was day 15.
In 32 patients of the ECC group, median values for
fibrinogen, leucocyte, thrombocyte counts, CRP, and PCT
could be calculated for day 11–15 (Table 2). There were no
significant differences between the values of fibrinogen,
leucocyte, CRP, and PCT between patients treated with
hypothermia or for fever, but patients with fever had a
higher thrombocyte count than those treated with hypo-
thermia (p = 0.022). There were no significant differences
between the values of patients with and patients without
TEE.
Discussion
To our knowledge, this is the first study of a large cohort of
intensive care patients who were treated with ECC and
followed for the occurrence of TEE. In a small cohort
group of patients (n = 11) with traumatic head injury and
treated with ECC, Simosa et al. [8] found a DVT incidence
of 50 %.
In this study, we found a significantly higher risk for
developing a TEE in ECC patients (37 %) compared to the
control group (5 %). In a large register study of more than
15,000 patients with aneurysmal SAH or intracerebral
hemorrhage, Kshettry et al. found a general incidence of
4 % for TEE. Unfortunately, they did not report their
results with respect to the type of catheters used. [11]. In
our study, there was also a significantly increased risk for
TEE in ECC patients treated for fever compared to those
treated with therapeutic hypothermia. This may be due to a
generally higher TEE risk in patients with an infection
[12], although only the thrombocyte count and no other
infection parameter was higher in fever patients compared
to those treated with therapeutic hypothermia. In the study
Table 1 Incidence of thrombosis, pulmonary embolism and installed Cava filters
All patients
(n = 122)
Patients with
central venous
lines (n = 79)
Patients with endovascular cooling catheters (n = 43)
All (n = 43) Treated for
fever (n = 21)
Treated with
hypothermia
(n = 22)
Thrombosis and pulmonary embolism
confirmed by sonography and/or CT scan
20 (16 %) 4 (5 %) 16 (37 %) 11 (52 %) 5 (23 %)
Thrombosis confirmed by sonography 15 (12 %) 4 (5 %) 11 (26 %) 7 (32 %) 4 (19 %)
Pulmonary embolism confirmed by CT scan 7 (6 %) 2 (3 %) 5 (12 %) 4 (19 %) 1 (5 %)
Cava filter installed 6 (5 %) 0 (0 %) 6 (14 %) 6 (27 %) 0 (0 %)
Table 2 Labor parameters analyzed
Fibrinogen median
for day 11–15 (g/l)
Leucocyte count
median for day 11–15 (g/l)
Thrombocyte count
median for day 11–15 (g/l)
CRP median for
day 11–15 (ng/l)
PCT median for
day 11–15 (lg/l)
All (n = 32) 6.0 (3.6–14.6) 9.33 (2.9–19.3) 193 (85–859) 53 (2–388) 0.16 (0.01–5.57)
Fever (n = 17) 6.1 (4.8–17) 9.39 (2.94–17) 253 (134–859) 65 (15–388) 0.16 (0.05–5.57)
Hypothermia (n = 15) 5.6 (3.6–13) 9.28 (6.2–16.7) 152 (85–459) 44 (2.2–250) 0.16 (0.01–0.62)
Thrombosis (n = 15) 5.7 (3.6–14.6) 9.44 (2.94–16.82) 253 (97–522) 65 (2.2–388) 0.15 (0.03–5.57)
No thrombosis (n = 17) 6.3 (4.1–13) 9.06 (5.28–19.33) 186 (85–859) 47 (15–250) 0.19 (0.01–0.62)
Values are given as median for day 11–15 after ECC onset and range
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population of Kshettry et al., infectious complications were
a significant risk factor to suffer from TEE.
Pulmonary embolism occurred more frequently in ECC
patients (12 %) compared to patients who had only a CVL
(3 %). Kshettry reported in their study population a pul-
monary embolism incidence of 1 %. Several limitations of
the study have to be considered: the robustness of the
results is limited. For multiple logistic regression analyses,
the patient number was too small. The mortality, further-
more, in the ECC group was higher than in the control
group. This was probably due to the fact that the severity
grade in patients of the ECC group was higher. Further
studies have to distinguish if the TEE risk is also increased
in patients with other diseases than SAH treated with en-
dovascular cooling catheters.
The higher incidence of TEE in the ECC group might
have been influenced by the central venous access site. A
recent Cochrane analysis showed that the incidence of
thrombotic complications is as high as 22 % with femoral
central venous access routes, compared to subclavian
catheters with only 1.9 %, whereas no significant differ-
ences exist between femoral and jugular catheters [13]. In
the present series, all ECCs were inserted into the femoral
vein, whereas most CVLs were inserted in the subclavian
vein. The risk for TEE for ECC inserted in the subclavian
vein should be examined exclusively. Moreover, in a future
prospective study, it is recommended to perform routine
screening Doppler examinations to detect asymptomatic
TEE as well.
Conclusion
Our data show that treatment with ECC increases the risk
of TEE in SAH patients. Therefore, especially for fever
control, non-invasive devices for surface cooling should be
the first choice.
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